PrLZ is expressed in normal prostate development and in human prostate cancer progression

Ruoxiang Wang, Jianchun Xu, Nicola Mabjeesh, Guodong Zhu, Jianguang Zhou, Mahul Amin, Dalin He, Fray F. Marshall, Haiyen E. Zhau, Leland W.K. Chung

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Purpose: We previously reported the isolation and characterization of PrLZ, a novel prostate-specific and androgen-responsive gene of the tumor protein D52 family at chromosome 8q21.1. PrLZ is the only known gene in this locus with prostate specificity. Expression level of PrLZ was elevated specifically in cancer cells, suggesting its association with malignancy. Experimental Design: To define its biological function in themorphogenesis, development, and functional maturation of the prostate gland and to gain further insight into its role in prostate cancer, we examined PrLZ expression in prostate specimens during early embryonic development and in adult tissue. Results: PrLZ first appears in the nuclei of the prostate epithelia at 16 weeks of gestation before its distribution in the cytoplasm at later ages. Its expression peaks at 24 years of age, declines at 31 years of age, and maintains a minimal level in later age. On prostate cancer development, PrLZ expression is reactivated, and its expression increases from primary localized tumor to bone metastasis. Overexpression of PrLZ in prostate cancer cells accelerates their growth in vitro and tumor formation in vivo. Conclusion: This work identifies PrLZ as amarker for prostate cancer progression and metastasis, and its pattern of expressionis suggestive of a proto-oncogene.

Original languageEnglish (US)
Pages (from-to)6040-6048
Number of pages9
JournalClinical Cancer Research
Volume13
Issue number20
DOIs
StatePublished - Oct 15 2007
Externally publishedYes

Fingerprint

Human Development
Prostate
Prostatic Neoplasms
Neoplasms
Neoplasm Metastasis
Proto-Oncogenes
Androgens
Embryonic Development
Cytoplasm
Research Design
Epithelium
Chromosomes
Bone and Bones
Pregnancy
Growth
Genes
Proteins

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

PrLZ is expressed in normal prostate development and in human prostate cancer progression. / Wang, Ruoxiang; Xu, Jianchun; Mabjeesh, Nicola; Zhu, Guodong; Zhou, Jianguang; Amin, Mahul; He, Dalin; Marshall, Fray F.; Zhau, Haiyen E.; Chung, Leland W.K.

In: Clinical Cancer Research, Vol. 13, No. 20, 15.10.2007, p. 6040-6048.

Research output: Contribution to journalArticle

Wang, R, Xu, J, Mabjeesh, N, Zhu, G, Zhou, J, Amin, M, He, D, Marshall, FF, Zhau, HE & Chung, LWK 2007, 'PrLZ is expressed in normal prostate development and in human prostate cancer progression', Clinical Cancer Research, vol. 13, no. 20, pp. 6040-6048. https://doi.org/10.1158/1078-0432.CCR-07-0640
Wang, Ruoxiang ; Xu, Jianchun ; Mabjeesh, Nicola ; Zhu, Guodong ; Zhou, Jianguang ; Amin, Mahul ; He, Dalin ; Marshall, Fray F. ; Zhau, Haiyen E. ; Chung, Leland W.K. / PrLZ is expressed in normal prostate development and in human prostate cancer progression. In: Clinical Cancer Research. 2007 ; Vol. 13, No. 20. pp. 6040-6048.
@article{1a65cf0d114d48c1a7689c1790207721,
title = "PrLZ is expressed in normal prostate development and in human prostate cancer progression",
abstract = "Purpose: We previously reported the isolation and characterization of PrLZ, a novel prostate-specific and androgen-responsive gene of the tumor protein D52 family at chromosome 8q21.1. PrLZ is the only known gene in this locus with prostate specificity. Expression level of PrLZ was elevated specifically in cancer cells, suggesting its association with malignancy. Experimental Design: To define its biological function in themorphogenesis, development, and functional maturation of the prostate gland and to gain further insight into its role in prostate cancer, we examined PrLZ expression in prostate specimens during early embryonic development and in adult tissue. Results: PrLZ first appears in the nuclei of the prostate epithelia at 16 weeks of gestation before its distribution in the cytoplasm at later ages. Its expression peaks at 24 years of age, declines at 31 years of age, and maintains a minimal level in later age. On prostate cancer development, PrLZ expression is reactivated, and its expression increases from primary localized tumor to bone metastasis. Overexpression of PrLZ in prostate cancer cells accelerates their growth in vitro and tumor formation in vivo. Conclusion: This work identifies PrLZ as amarker for prostate cancer progression and metastasis, and its pattern of expressionis suggestive of a proto-oncogene.",
author = "Ruoxiang Wang and Jianchun Xu and Nicola Mabjeesh and Guodong Zhu and Jianguang Zhou and Mahul Amin and Dalin He and Marshall, {Fray F.} and Zhau, {Haiyen E.} and Chung, {Leland W.K.}",
year = "2007",
month = "10",
day = "15",
doi = "10.1158/1078-0432.CCR-07-0640",
language = "English (US)",
volume = "13",
pages = "6040--6048",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "20",

}

TY - JOUR

T1 - PrLZ is expressed in normal prostate development and in human prostate cancer progression

AU - Wang, Ruoxiang

AU - Xu, Jianchun

AU - Mabjeesh, Nicola

AU - Zhu, Guodong

AU - Zhou, Jianguang

AU - Amin, Mahul

AU - He, Dalin

AU - Marshall, Fray F.

AU - Zhau, Haiyen E.

AU - Chung, Leland W.K.

PY - 2007/10/15

Y1 - 2007/10/15

N2 - Purpose: We previously reported the isolation and characterization of PrLZ, a novel prostate-specific and androgen-responsive gene of the tumor protein D52 family at chromosome 8q21.1. PrLZ is the only known gene in this locus with prostate specificity. Expression level of PrLZ was elevated specifically in cancer cells, suggesting its association with malignancy. Experimental Design: To define its biological function in themorphogenesis, development, and functional maturation of the prostate gland and to gain further insight into its role in prostate cancer, we examined PrLZ expression in prostate specimens during early embryonic development and in adult tissue. Results: PrLZ first appears in the nuclei of the prostate epithelia at 16 weeks of gestation before its distribution in the cytoplasm at later ages. Its expression peaks at 24 years of age, declines at 31 years of age, and maintains a minimal level in later age. On prostate cancer development, PrLZ expression is reactivated, and its expression increases from primary localized tumor to bone metastasis. Overexpression of PrLZ in prostate cancer cells accelerates their growth in vitro and tumor formation in vivo. Conclusion: This work identifies PrLZ as amarker for prostate cancer progression and metastasis, and its pattern of expressionis suggestive of a proto-oncogene.

AB - Purpose: We previously reported the isolation and characterization of PrLZ, a novel prostate-specific and androgen-responsive gene of the tumor protein D52 family at chromosome 8q21.1. PrLZ is the only known gene in this locus with prostate specificity. Expression level of PrLZ was elevated specifically in cancer cells, suggesting its association with malignancy. Experimental Design: To define its biological function in themorphogenesis, development, and functional maturation of the prostate gland and to gain further insight into its role in prostate cancer, we examined PrLZ expression in prostate specimens during early embryonic development and in adult tissue. Results: PrLZ first appears in the nuclei of the prostate epithelia at 16 weeks of gestation before its distribution in the cytoplasm at later ages. Its expression peaks at 24 years of age, declines at 31 years of age, and maintains a minimal level in later age. On prostate cancer development, PrLZ expression is reactivated, and its expression increases from primary localized tumor to bone metastasis. Overexpression of PrLZ in prostate cancer cells accelerates their growth in vitro and tumor formation in vivo. Conclusion: This work identifies PrLZ as amarker for prostate cancer progression and metastasis, and its pattern of expressionis suggestive of a proto-oncogene.

UR - http://www.scopus.com/inward/record.url?scp=35948961547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35948961547&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-07-0640

DO - 10.1158/1078-0432.CCR-07-0640

M3 - Article

VL - 13

SP - 6040

EP - 6048

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 20

ER -